«A.Zalesov & Partners» win a dispute with the Federal Antimonopoly Service of Russia on the cancer treatment medication Axitinib
On November 12, 2025, Russian IP Court held a hearing in case A40-264483/2024. Associates of «A.Zalesov & Partners», representing the Applicant, proved that actions of «AkselPharm» in introducing the medicinal product Axitinib into civil circulation under the registration certificate No. LP-No. (003110)-(PG-RU) dated August 31, 2023, do not constitute unfair competition.
17.11.2025
Aleksey Zalesov Darya Kushnarenko Life Science Antitrust law